Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of 1,4-Butanediol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 6/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,4-Butanediol SCHEMBL924158 | 1.00 | CA5A (0.50) | CA5ACA5BSMN1; SMN2GPR84FFAR1 | |
| 1,6-Hexanediol SCHEMBL28157698 | 0.96 | CA5A (0.46) | CA5ACA5BSMN1; SMN2GPR84FFAR1 | |
| 1,4-Butanediol SCHEMBL27884349 | 0.96 | CA5A (0.46) | CA5ACA5BSMN1; SMN2GPR84FFAR1 | |
| 1,5-Pentanediol SCHEMBL923627 | 0.96 | CA5A (0.46) | CA5ACA5BSMN1; SMN2GPR84FFAR1 | |
| 1,4-Butanediol SCHEMBL921711 | 0.96 | CA5A (0.46) | CA5ACA5BSMN1; SMN2GPR84FFAR1 | |
| 1,5-Pentanediol SCHEMBL1896067 | 0.96 | CA5A (0.46) | CA5ACA5BSMN1; SMN2GPR84FFAR1 | |
| Sulfuric Acid SCHEMBL920405 | 0.92 | CA5A (0.50) | CA5ACA5BSMN1; SMN2GPR84FFAR1 | |
| Sulfuric Acid SCHEMBL710960 | 0.92 | CA5A (0.50) | CA5ACA5BSMN1; SMN2GPR84FFAR1 | |
| Sulfuric Acid SCHEMBL28086720 | 0.88 | CA5A (0.46) | CA5ACA5BSMN1; SMN2GPR84FFAR1 | |
| Sulfuric Acid SCHEMBL923060 | 0.88 | CA5A (0.46) | CA5ACA5BSMN1; SMN2GPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-220209012-U | Battery pole piece and winding battery | 微宏动力系统（湖州）有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-117012895-A | Battery pole piece, winding battery and preparation method thereof | 微宏动力系统（湖州）有限公司 | 2023-11-07 | — | — | CN | claimed |
| CN-116031482-A | Secondary battery electrolyte, preparation method thereof, secondary battery and electronic equipment | 华为终端有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-112225719-B | Synthetic method of cyclic sulfate | 湖南阿斯达新材料有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-109847099-B | Multilayer soft tissue repair material and preparation method thereof | 四川大学华西医院 | 2022-04-01 | — | — | CN | claimed |
| CN-111864275-B | Battery cell, preparation method thereof and lithium ion battery | 北京卫蓝新能源科技有限公司 | 2021-10-15 | — | — | CN | claimed |
| CN-108258312-B | Non-aqueous electrolyte of high-voltage lithium ion battery | 珠海市赛纬电子材料股份有限公司 | 2021-05-11 | — | — | CN | claimed |
| CN-110707357-B | Gel polymer electrolyte with core-shell structure and preparation method and application thereof | 北京卫蓝新能源科技有限公司 | 2021-05-07 | — | — | CN | claimed |
| CN-112225719-A | Synthetic method of cyclic sulfate | 湖南阿斯达新材料有限公司 | 2021-01-15 | — | — | CN | claimed |
| CN-111864275-A | Battery cell, preparation method thereof and lithium ion battery | 北京卫蓝新能源科技有限公司 | 2020-10-30 | — | — | CN | claimed |
| US-8470472-B2 | Non-aqueous electrolyte secondary battery, and method for fabricating non-aqueous electrolyte secondary battery | GS YUASA INTERNATIONAL LTD. (JP) | 2013-06-25 | — | — | US | claimed |
| US-20120064396-A1 | NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY, AND METHOD FOR FABRICATNG NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | GS YUASA INTERNATIONAL LTD. (JP) | 2012-03-15 | — | — | US | claimed |
| US-20110002875-A1 | METHOD FOR TREATING AMYLOIDOSIS | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2011-01-06 | — | — | US | claimed |
| EP-1064013-A4 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2005-05-11 | — | — | EP | claimed |
| US-20030108595-A1 | Method for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON | 2003-06-12 | — | — | US | claimed |
| US-20010048941-A1 | Method for treating amyloidosis | QUEEN'S UNIVERSITY OF KINGSTON | 2001-12-06 | — | — | US | claimed |
| EP-1064013-A1 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | University of Washington (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999045947-A9 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999045947-A1 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIVERSITY OF WASHINGTON (US) | 1999-09-16 | — | — | WO | claimed |
| US-5643562-A | ANTIDEPOSIT AGENTS FOR PROTEINS FOR MEDICAL DIAGNOSIS OF DISEASES | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 1997-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108595-A1 | Method for treating amyloidosis | TTR, IAPP, APP | CA5A 1465/4885CA5B 1234/4885SMN1; SMN2 368/4885 |
| US-20010048941-A1 | Method for treating amyloidosis | TTR, APOB, NEFM | CA5A 1670/4885CA5B 1887/4885SMN1; SMN2 491/4885 |
| US-20110002875-A1 | METHOD FOR TREATING AMYLOIDOSIS | TTR, IAPP, APP | CA5A 1465/4885CA5B 1234/4885SMN1; SMN2 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.